Characterization and Management of Cytokine Release Syndrome From the MonumenTAL-1 Study of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma

[Introduction] Cytokine release syndrome (CRS) is a common adverse event associated with T-cell redirection therapies (TCRT), including talquetamab, the first GPRC5D × CD3 bispecific antibody approved for relapsed/refractory multiple myeloma (RRMM). We describe CRS with talquetamab and implications...

Descripción completa

Detalles Bibliográficos
Autores: Donk, Niels W. C. J. van de, Chari, Ajai, Martin, Thomas, Krishnan, Amrita, Rasche, Leo, Ye, Jing Christine, Popat, Rakesh, Lipe, Brea, Rodríguez, César, Schinke, Carolina, Skerget, Sheri, Vishwamitra, Deeksha, Verona, Raluca, Gong, Jue, Singh, Indrajeet, Campagna, Michela, Masterson, Tara, Hilder, Brandi, Tolbert, Jaszianne, Renaud, Thomas, Smit, M. Damiette, Heuck, Christoph, Mateos, Maria Victoria
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/423493
Acceso en línea:http://hdl.handle.net/10261/423493
Access Level:acceso abierto
Palabra clave:Clinical management |
Cytokine release syndrome
GPRC5D
Interleukin-6
Talquetamab
Tocilizumab
Descripción
Sumario:[Introduction] Cytokine release syndrome (CRS) is a common adverse event associated with T-cell redirection therapies (TCRT), including talquetamab, the first GPRC5D × CD3 bispecific antibody approved for relapsed/refractory multiple myeloma (RRMM). We describe CRS with talquetamab and implications for clinical practice.

Similares en LA Referencia